Literature DB >> 32329389

Tofacitinib-induced remission in refractory adult-onset Still's disease complicated by macrophage activation syndrome.

M Honda1, M Moriyama1, M Kondo1, S Kumakura1,2, Y Murakawa1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32329389     DOI： 10.1080/03009742.2020.1729405

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN： 0300-9742            Impact factor:   3.641


× No keyword cloud information.
  4 in total

1.  Effectiveness and Safety of JAK Inhibitors in Autoinflammatory Diseases: A Systematic Review.

Authors:  Zhivana Boyadzhieva; Nikolas Ruffer; Gerd Burmester; Anne Pankow; Martin Krusche
Journal:  Front Med (Lausanne)       Date:  2022-06-27

Review 2.  Progress in Biological Therapies for Adult-Onset Still's Disease.

Authors:  Paola Galozzi; Sara Bindoli; Andrea Doria; Paolo Sfriso
Journal:  Biologics       Date:  2022-04-21

3.  Case Report: Baricitinib as an Alternative in the Maintenance Therapy for Macrophage Activation Syndrome Secondary to Nodular Panniculitis.

Authors:  Guanqun Yi; Zhengping Huang; Zhixiang Huang; Yunqing Wang; Weiming Deng; Shaoling Zheng; Tianwang Li
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

Review 4.  An Update on the Pathogenic Role of Macrophages in Adult-Onset Still's Disease and Its Implication in Clinical Manifestations and Novel Therapeutics.

Authors:  Po-Ku Chen; Der-Yuan Chen
Journal:  J Immunol Res       Date:  2021-06-20       Impact factor: 4.818
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.